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Background-—Previous studies have reported a protective effect of obesity compared with normal body mass index (BMI) in
patients undergoing percutaneous coronary intervention (PCI). However, it is unclear whether this effect extends to the extremely
obese. In this large multicenter registry-based study, we sought to examine the relationship between BMI and long-term clinical
outcomes following PCI, and in particular to evaluate the association between extreme obesity and long-term survival after PCI.
Methods and Results-—This cohort study included 25 413 patients who underwent PCI between January 1, 2005 and June 30,
2017, who were prospectively enrolled in the Melbourne Interventional Group registry. Patients were stratified by World Health
Organization–defined BMI categories. The primary end point was National Death Index–linked mortality. The median length of
follow-up was 4.4 years (interquartile range 2.0-7.6 years). Of the study cohort, 24.8% had normal BMI (18.5-24.9 kg/m2), and
3.3% were extremely obese (BMI ≥40 kg/m2). Patients with greater degrees of obesity were younger and included a higher
proportion of diabetics (P<0.001). After adjustment for age and comorbidities, a J-shaped association was observed between
different BMI categories and adjusted hazard ratio (HR) for long-term mortality (normal BMI, HR 1.00 [ref]; overweight, HR 0.85,
95% CI 0.78-0.93, P<0.001; mild obesity, HR 0.85, 95% CI 0.76-0.94, P=0.002; moderate obesity, HR 0.95, 95% CI 0.80-1.12,
P=0.54; extreme obesity HR 1.33, 95% CI 1.07-1.65, P=0.01).
Conclusions-—An obesity paradox is still apparent in contemporary practice, with elevated BMI up to 35 kg/m2 associated with
reduced long-term mortality after PCI. However, this protective effect appears not to extend to patients with extreme obesity. ( J
Am Heart Assoc. 2019;8:e012860. DOI: 10.1161/JAHA.119.012860.)
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O besity is a growing health concern worldwide, particu-larly in developed countries, where there has been an
unprecedented rise in the proportion of overweight and obese
individuals in the population.1,2 Obesity is associated with
numerous adverse health outcomes including coronary artery
disease, stroke, heart failure, and diabetes mellitus and has
also been linked to higher rates of mortality.3,4 Despite this,
several studies in the past have described an “obesity
paradox” whereby obesity appears to confer a protective
effect compared with normal body mass index (BMI), in a
variety of medical conditions.5-9 This was also described in
the setting of percutaneous coronary intervention (PCI), where
overweight and obese patients were shown to have lower
rates of short-term mortality compared with normal-BMI
individuals.10-12 A meta-analysis of over 200 000 patients
with myocardial infarction also reported that obese patients
have a 30% to 40% lower mortality compared with individuals
with normal BMI over a 1- to 3-year follow-up period.13
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However, more recent studies in patients in the contemporary
era of PCI have produced conflicting results.14-18 In particular,
despite extreme obesity (BMI≥40 kg/m2) increasing in
prevalence among patients undergoing PCI, few studies have
examined long-term clinical outcomes in this group.19,20
Studies examining in-hospital mortality of patients undergoing
PCI have suggested that although lesser degrees of obesity
may be protective, this effect does not extend to patients with
extreme obesity.12,19 However, very few earlier studies have
assessed mortality rates beyond 12 months in patients with
extreme obesity undergoing PCI for both stable angina and
acute coronary syndromes.
In this study we therefore sought to determine whether an
obesity paradox persists in contemporary PCI practice over
long-term follow-up and, in particular, to further evaluate the
association between extreme obesity and long-term clinical
outcomes after PCI.
Methods
Due to the sensitive nature of the data collected for this
study, requests to access the data set from qualified
researchers trained in human subject confidentiality protocols
may be sent to Ms Angela Brennan of Monash University at
angela.brennan@monash.edu.
This was a cohort study of patients undergoing PCI
between January 1, 2005 and June 30, 2017 inclusive,
enrolled prospectively in the MIG (Melbourne Interventional
Group) registry. All consecutive adult patients undergoing PCI
were eligible for inclusion. We excluded patients in whom
height and/or weight was not recorded at the time of PCI, and
therefore BMI could not be calculated. Patients who could not
be considered for linkage to the Australian NDI (National
Death Index) mortality database due to incomplete case
information at the time the registry data were sent for linkage
were also excluded (n=267).
For all patients included in this study, BMI was calculated
by dividing weight (in kilograms) by the square of the height
(in meters). Patients were classified into the following 6
groups by their BMI as per the World Health Organization
Classification System: underweight (BMI<18.5 kg/m2), nor-
mal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25-
29.9 kg/m2), class I obese (BMI 30-34.9 kg/m2), class II
obese (BMI 35-39.9 kg/m2), and class III obese
(BMI≥40 kg/m2).21 However, due to the very small sample
size in the underweight group (n=232), which is likely to make
comparisons with the other groups imprecise, these patients
were excluded in deriving our final study cohort.
The MIG registry is a multicenter Australian PCI registry
that collects data from 6 participating hospitals, 4 of which
are located in metropolitan Melbourne, and 2 hospitals are
located in large regional centers.22 Baseline demographic,
clinical, procedural, and in-hospital outcome data are prospec-
tively recorded on case-report forms using standardized
definitions for all fields (Table S1). Relevant information for
30-day outcomes was obtained through telephone follow-up
with further review of medical records performed in patients
who reported any events.23 In addition, mortality data were
obtained by linkage to the Australian NDI, a database housed
at the Australian Institute of Health and Welfare that contains
records of all deaths occurring in Australia since 1980. The
censoring date for linkage with the NDI in this study was
August 1, 2017. Successful matching of patients through this
linkage process was achieved in 99.0% of all patients in the
study cohort. The MIG registry has an “opt-out” consent
process as previously described and has been granted ethics
approval by the ethics committee at The Alfred Hospital
(approval number 92/04) as well as by committees at each
participating hospital.22,23
Baseline and procedural characteristics, as well as in-
hospital and 30-day outcomes, were compared among the
groups. The primary end point was NDI-linked long-term
mortality. Secondary end points included death (all-cause
mortality and cardiac mortality), myocardial infarction,
target vessel revascularization and major adverse cardio-
vascular events at 30-day follow-up. Major adverse cardio-
vascular events were defined as a composite of death,
myocardial infarction, and target vessel revascularization.
Major bleeding was defined as a fall in hemoglobin by
>3.0 g/dL and/or requiring transfusion. Use of antiplatelet
Clinical Perspective
What Is New?
• This study shows that the obesity paradox persists in
contemporary percutaneous coronary intervention practice,
whereby overweight and obese patients have better post–
percutaneous coronary intervention long-term survival than
those with normal body mass index.
• However, our study demonstrates that this protective effect
does not extend to patients with extreme obesity.
What Are the Clinical Implications?
• Our study demonstrates that there is a threshold effect to
the obesity paradox, which is important for clinicians to
recognize when risk-stratifying patients.
• We also show that patients with normal body mass index
are less likely to receive appropriate secondary prevention
therapy compared with their higher body mass index
counterparts.
• More attention needs to be paid to reducing this treatment
gap in clinical practice, which may help improve outcomes
in patients with normal body mass index.
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therapy, b-blockers, angiotensin-converting enzyme inhibi-
tors/angiotensin receptor blockers, and cholesterol-lowering
therapies (statins, fibrates, and ezetimibe) at 30 days after
the index PCI was also compared among the groups.
Prescription of postdischarge medications was at the
discretion of the treating physician according to contem-
porary guidelines.
Continuous variables are expressed as meanSD and were
compared using a Kruskal-Wallis equality-of-populations rank
test. Categorical data are expressed as numbers and
percentages and compared using the Pearson chi-squared
test or Fisher exact test as appropriate. The Kaplan-Meier
method was used to estimate post-PCI survival rates, and the
log-rank test was used for survival comparisons. Cox propor-
tional hazard modeling was used to identify independent
predictors of the primary end point of NDI-linked long-term
mortality. In this model in addition to BMI group, 28 other
clinically relevant variables such as sex, cardiovascular risk
Table 1. Baseline Characteristics
BMI 18.5 to
24.9 kg/m2
BMI 25.0 to
29.9 kg/m2
BMI 30.0 to
34.9 kg/m2
BMI 35.0 to
39.9 kg/m2 BMI ≥40 kg/m2 P for Trend
N (%) 6305 (24.6) 10 608 (41.4) 5780 (22.5) 1874 (7.3) 846 (3.3)
Mean ageSD, y 67.012.4 64.411.8 62.711.6 61.010.7 59.210.7 <0.001
Age >80 years 966 (15.3) 944 (8.9) 340 (5.9) 56 (3.0) 19 (2.3) <0.001
Female 1664 (26.4) 1967 (18.5) 1281 (22.2) 586 (31.3) 354 (41.8) <0.001
Diabetes mellitus 1022 (16.2) 2419 (22.8) 1735 (30.0) 784 (41.8) 381 (45.0) <0.001
Hypertension 3731 (59.2) 6848 (64.6) 4233 (73.3) 1475 (78.8) 675 (79.8) <0.001
Dyslipidemia 3836 (61.0) 7081 (66.9) 4140 (71.6) 1385 (74.0) 611 (72.4) <0.001
Current or past smoker 4016 (64.7) 6975 (66.7) 4001 (70.5) 1262 (68.4) 585 (70.1) <0.001
Family history of coronary artery disease 2096 (34.7) 3939 (38.9) 2236 (40.6) 726 (40.7) 370 (46.1) <0.001
eGFR >60 mL/min per 1.73 m2 4594 (75.9) 8019 (79.0) 4346 (77.7) 1400 (77.7) 602 (74.1)
0.694eGFR 30 to 60 mL/min per 1.73 m2 1242 (20.5) 1864 (18.4) 1108 (19.8) 355 (19.7) 181 (22.3)
eGFR <30 mL/min per 1.73 m2 216 (3.6) 262 (2.6) 143 (2.6) 48 (2.7) 30 (3.7)
Chronic obstructive pulmonary disease 505 (8.0) 545 (5.1) 341 (5.9) 109 (5.8) 53 (6.3) <0.001
Obstructive sleep apnea 98 (1.6) 305 (2.9) 366 (6.3) 245 (13.1) 175 (20.7) <0.001
Peripheral vascular disease 439 (7.0) 547 (5.2) 347 (6.0) 109 (5.8) 36 (4.3) 0.007
Previous stroke 427 (6.8) 547 (5.2) 320 (5.5) 108 (5.8) 51 (6.0) 0.072
Previous myocardial infarction 1563 (24.8) 2717 (25.6) 1600 (27.7) 535 (28.6) 236 (28.0) <0.001
Previous percutaneous coronary
intervention
1543 (24.5) 2734 (25.8) 1610 (27.9) 533 (28.4) 227 (26.8) <0.001
Previous coronary artery bypass graft
surgery
457 (7.3) 880 (8.3) 488 (8.4) 179 (9.6) 49 (5.8) 0.107
Clinical presentation
Stable angina 1832 (29.1) 3597 (33.9) 2075 (35.9) 708 (37.8) 264 (31.2) <0.001
Unstable angina 513 (8.1) 870 (8.2) 448 (7.8) 163 (8.7) 66 (7.8) 0.856
NSTEMI 1778 (28.2) 2821 (26.6) 1700 (29.4) 569 (30.4) 291 (34.4) <0.001
STEMI 2180 (34.6) 3318 (31.3) 1554 (26.9) 434 (23.2) 224 (26.5) <0.001
Cardiogenic shock 257 (4.1) 286 (2.7) 145 (2.5) 32 (1.7) 21 (2.5) <0.001
Out-of-hospital cardiac arrest 200 (3.2) 315 (3.0) 148 (2.6) 38 (2.0) 18 (2.1) 0.001
Mean LV ejection fractionSD 52.211.0 52.810.4 53.29.9 53.49.8 53.59.9 <0.001
LV ejection fraction <30% 130 (2.3) 157 (1.7) 62 (1.2) 22 (1.4) 8 (1.1)
<0.001LV ejection fraction 30% to 45% 1295 (2.3) 157 (1.7) 62 (1.2) 22 (1.4) 8 (1.1)
LV ejection fraction >45% 4236 (74.8) 7318 (77.8) 4001 (79.5) 1289 (80.9) 598 (81.7)
Data expressed as meanSD or numbers (%).
BMI indicates body mass index; eGFR, estimated glomerular filtration rate; LV, left ventricular; NSTEMI, non–ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.
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factors including diabetes mellitus, hypertension, and renal
impairment, history of previous myocardial infarction and/or
previous stroke, disease extent on angiography, and type of
stent used were considered. Aside from the BMI group, only
variables with a P<0.10 on univariate analysis that were not
collinear were entered into a stepwise backward selection
modeling process for multivariable assessment. Complete
case analysis was performed for purposes of multivariable
modeling (ie, patients with missing values were excluded). The
proportion of missing variables was <1% for all variables
except smoking status (1.6%), estimated glomerular filtration
rate (3.9%), family history of coronary artery disease (4.5%),
30-day medications (7.3%), and left ventricular ejection
fraction (11.7%).
All statistical analyses were performed using Stata 13.1
software (StataCorp LP, College Station, TX). P<0.05 was
considered to be statistically significant.
Results
In total, 25 413 patients were included in this analysis. Of
these, 6305 (24.6%) were in the normal BMI category, 10 608
(41.4%) were overweight, 5780 (22.5%) had mild (class I)
obesity, 1874 (7.3%) had moderate (class II) obesity, and 846
(3.3%) had extreme (class III) obesity. The mean age of the
whole study cohort was 64.212.0 years, and 23.0% were
female.
Table 2. Procedural Characteristics
BMI 18.5 to
24.9 kg/m2
BMI 25.0 to
29.9 kg/m2
BMI 30.0 to
34.9 kg/m2
BMI 35.0 to
39.9 kg/m2 BMI ≥40 kg/m2 P for Trend
Lesion characteristics
Multivessel disease 3712 (59.0) 6248 (59.0) 3383 (58.6) 1085 (58.1) 461 (54.6) 0.054
Left main lesion 89 (1.2) 135 (1.1) 76 (1.1) 22 (1.0) 7 (0.7) 0.243
Chronic total occlusion lesion 229 (3.1) 480 (3.8) 269 (4.0) 98 (4.5) 37 (3.7) 0.003
ACC/AHA type B2/C lesion 4221 (56.2) 7075 (56.2) 3804 (56.1) 1304 (59.2) 566 (56.3) 0.206
Procedural details
Radial access 1434 (22.7) 2675 (25.2) 1594 (27.6) 549 (29.3) 290 (34.3)
<0.001
Femoral access 4871 (77.3) 7932 (74.8) 4186 (72.4) 1325 (70.7) 556 (65.7)
Arterial access closure device used 645 (10.2) 1123 (10.6) 587 (10.2) 223 (11.9) 121 (14.3) 0.004
Balloon angioplasty only 411 (6.5) 657 (6.2) 410 (7.1) 130 (6.9) 56 (6.6)
0.001Bare metal stent 2471 (39.2) 4035 (38.0) 2089 (36.1) 628 (33.5) 308 (36.4)
Drug-eluting stent 3423 (54.3) 5916 (55.8) 3281 (56.8)) 1116 (59.6) 482 (57.0)
Intra-aortic balloon pump use 136 (2.2) 177 (1.7) 82 (1.4) 17 (0.9) 9 (1.1) <0.001
Thrombectomy device used 520 (8.0) 884 (8.0) 406 (6.8) 105 (5.4) 49 (5.4) <0.001
Glycoprotein IIb/IIIa inhibitors 1854 (29.4) 2991 (28.2) 1441 (25.0) 431 (23.0) 197 (23.3) <0.001
Complications
Dissection 339 (4.5) 533 (4.2) 265 (3.9) 84 (3.8) 32 (3.2) 0.004
Perforation 24 (0.3) 39 (0.3) 12 (0.2) 5 (0.2) 0 (0.0) 0.011
Transient/persistent no-reflow 280 (3.9) 350 (2.9) 200 (3.1) 58 (2.7) 32 (3.3) 0.019
Unsuccessful PCI 334 (5.3) 514 (4.9) 310 (5.4) 102 (5.4) 48 (5.7) 0.440
Data expressed as meanSD, or numbers (%).
ACC/AHA indicates American College of Cardiology/American Heart Association; BMI, body mass index; PCI, percutaneous coronary intervention.
Figure 1. Kaplan-Meier curves of long-term survival by body
mass index group.
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Baseline Characteristics
Table 1 shows the baseline characteristics of the study cohort
stratified by BMI groups. With increasing BMI, patients were
younger and had more cardiovascular risk factors such as
diabetes mellitus (all P<0.001). The proportion of women was
highest at both extremes of BMI and lowest in the overweight
group. With increasing BMI, the proportion of patients who
presented with non–ST-elevation acute coronary syndromes
increased, whereas the proportion of patients who presented
with ST-elevation myocardial infarction, out-of-hospital car-
diac arrest, and cardiogenic shock decreased (P≤0.001).
Procedual characteristics are shown in Table 2. As BMI
increased, there was more radial access and less femoral
access use (P<0.001). There were no significant differences in
extent of coronary artery disease or lesion complexity by BMI
group. Drug-eluting stents were more frequently implanted in
the higher BMI groups (P<0.001). Procedural complications
such as coronary dissection and perforation were overall
infrequent, but less common in the higher BMI groups (both
P<0.04), although the overall proportion of unsuccessful PCIs
was similar across the BMI groups (P=0.440). There was also a
reduction in the proportion of patients with severe left
ventricular systolic dysfunction (left ventricular ejection frac-
tion <30%) at the time of PCI, with increasing BMI (P<0.001).
Clinical Outcomes
In-hospital and 30-day outcomes are shown in Table 3. A 30-
day follow-up was completed in 99.6% of the study cohort.
There was a J-shaped association between BMI and both in-
hospital and 30-day mortality, with a steady fall in mortality
from the normal BMI group to the moderate obesity group,
followed by a substantial rise in mortality in the extreme
obesity group (P<0.001). A similar pattern of association was
also seen with in-hospital and 30-day major adverse cardio-
vascular events. With increasing BMI, there was a significant
stepwise reduction in in-hospital bleeding (P<0.001). There
were no significant differences in 30-day readmission rates
across the BMI groups.
All-cause mortality data beyond 30 days were obtained
using linkage with the NDI database. Median length of follow-up
was 4.4 years (IQR 2.0-7.6 years) overall and similar in all the
Table 3. Clinical Outcomes
BMI 18.5 to
24.9 kg/m2
BMI 25.0 to
29.9 kg/m2
BMI 30.0 to
34.9 kg/m2
BMI 35.0 to
39.9 kg/m2 BMI ≥40 kg/m2 P for Trend
In-hospital outcomes
Death 142 (2.3) 175 (1.6) 74 (1.3) 20 (1.1) 16 (1.9) <0.001
Cardiac death 113 (1.8) 144 (1.4) 58 (1.0) 18 (1.0) 11 (1.3) 0.799
Periprocedural myocardial infarction 76 (1.2) 113 (1.1) 60 (1.0) 20 (1.1) 6 (0.7) 0.208
Heart failure 263 (4.2) 357 (3.4) 188 (3.3) 52 (2.8) 38 (4.5) 0.041
Acute kidney injury 111 (1.8) 191 (1.8) 87 (1.5) 21 (1.1) 23 (2.7) 0.591
Major bleeding 208 (3.3) 196 (1.9) 107 (1.9) 24 (1.3) 10 (1.2) <0.001
Stroke 24 (0.4) 22 (0.2) 22 (0.4) 4 (0.2) 1 (0.1) 0.380
Target vessel revascularization 77 (1.2) 115 (1.1) 69 (1.2) 19 (1.0) 11 (1.3) 0.931
MACE 265 (4.2) 374 (3.5) 181 (3.1) 58 (3.1) 31 (3.7) 0.007
30-day outcomes
Death 177 (2.8) 211 (2.0) 95 (1.7) 24 (1.3) 21 (2.5) <0.001
Cardiac death 133 (2.1) 161 (1.5) 71 (1.2) 21 (1.1) 13 (1.5) 0.774
Myocardial infarction 129 (2.1) 175 (1.7) 104 (1.8) 30 (1.6) 8 (1.0) 0.045
Stroke 38 (0.6) 33 (0.3) 25 (0.4) 8 (0.4) 1 (0.1) 0.084
Target vessel revascularization 146 (2.3) 234 (2.2) 133 (2.3) 52 (2.8) 20 (2.4) 0.452
Any readmission 751 (12.3) 1084 (10.5) 653 (11.6) 219 (12.0) 93 (11.3) 0.610
MACE 375 (6.0) 527 (5.0) 276 (4.8) 88 (4.7) 42 (5.0) 0.008
NDI-linked mortality
No. of deaths 1195 (19.2) 1423 (13.5) 751 (13.1) 225 (12.2) 118 (14.1) <0.001
Median follow-up time (IQR), y 4.4 (2.0-7.5) 4.5 (2.0-7.7) 4.4 (2.0-7.6) 4.1 (2.0-7.0) 3.9 (1.5-6.9) 0.047
Data expressed as median (IQR) or numbers (%). BMI indicates body mass index; IQR, interquartile range; MACE, major adverse cardiovascular events; NDI, national death index.
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groups (P=0.047). Patients with moderate obesity had the
lowest mortality rate (12.2%), whereas patients both with
normal BMI and extreme obesity were found to have a higher
mortality rate (19.2% and 14.1% respectively). The Kaplan-Meier
survival curves for the 5 BMI groups are shown in Figure 1, and
they confirm that patients with extreme obesity had signifi-
cantly lower long-term survival, compared to the other groups
(log rank P<0.001). Using Cox-proportional hazards modelling
with the normal BMI group as the reference category, a J-shaped
association between BMI and adjusted hazard ratio for NDI-
linked long-term mortality was observed (Figure 2). The
adjusted hazard ratio (HR) was highest for patients with
extreme obesity (HR 1.33, 95% CI 1.07-1.65). Being overweight
and havingmild obesity both appeared to be protective for long-
term NDI-linked mortality, with the latter group having the
lowest adjusted hazard ratio. The 3 strongest independent
predictors of NDI-linked long-term mortality were stage 4 to 5
chronic kidney disease, cardiogenic shock, and severe left
ventricular systolic dysfunction (HR 3.46, 2.98 and 2.50
respectively; all P<0.001) (Table 4).
Secondary Prevention Therapy
At 30 days post PCI, there were no significant differences in
use of aspirin, a second antiplatelet agent, or statins across
the BMI groups (all P>0.05) (Table 5). However, patients with
normal BMI were significantly less likely to receive a b-blocker
or angiotensin-converting enzyme inhibitor/angiotensin
receptor blocker compared with the other BMI groups
(P=0.003 and P<0.001 respectively).
Discussion
In this large, multicenter study evaluating the relationship
between BMI and long-term mortality in patients undergoing
PCI, we observed a J-shaped association between different
BMI groups and adjusted mortality risk, with patients at the
extremes of BMI experiencing the highest risk. Although an
obesity paradox was present with underweight patients
having the highest mortality out of all of the groups, it only
extended as far as patients with mild obesity. Therefore,
patients with extreme obesity remain at significantly
increased risk of long-term mortality compared with their
healthy weight and less obese counterparts.
The results of our study provide important additional
insights to the literature regarding outcomes after PCI in
patients with varying BMI. Our results are in accordance with
several large studies that have demonstrated a similar
association between in-hospital mortality and BMI
group.12,17,19 A feature of our study is that very few earlier
studies have assessed mortality rates beyond 12 months in
extremely obese patients undergoing PCI for both stable
Figure 2. Adjusted hazard ratios for NDI-linked mortality according to body mass index groups. BMI
indicates body mass index; NDI, National Death Index.
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angina and acute coronary syndromes. Holroyd et al evalu-
ated mortality up to 5 years after PCI in over 300 000
patients and also found that patients who were overweight
and obese (BMI >30 kg/m2) had reduced mortality risk up to
5 years compared with those with normal BMI.16 However,
the authors did not further subdivide obese patients further
into degrees of obesity, and therefore no conclusions can be
made as to whether extreme obesity remains protective.
Interestingly, a subgroup analysis on 15 603 patients who
underwent PCI and were enrolled in the Canadian APPROACH
registry with a median follow-up of 46 months showed that
whereas underweight patients had the highest adjusted
mortality risk and moderate obesity was protective, those
with extreme obesity had very similar adjusted mortality risk
to their normal weight counterparts.20 It is however difficult to
make comparisons with our study to understand reasons
behind this difference in outcomes as baseline or procedural
characteristics of the PCI subgroup were not presented
separately, and medication use data were only available for
12% of the whole cohort (including those not treated with
PCI). However, a similar neutral effect of severe obesity
(defined as BMI ≥35 kg/m2) compared with normal weight on
cardiovascular mortality risk after percutaneous or surgical
revascularization was also seen in a recent meta-analysis by
Sharma et al, suggesting that further large studies in this area
are required.24
Several possible mechanisms for the obesity paradox have
been postulated. In accordance with previous studies, our
data show that there was a linear relationship between BMI
and the prevalence of comorbidities such as diabetes mellitus,
hypertension, and dyslipidemia. However, patients with higher
BMI may be more likely to have been screened earlier and
aggressively treated for these cardiovascular risk factors,
thereby leading to better long-term outcomes despite obe-
sity.25 Overweight and mild-to-moderately obese patients
were also less likely to present with cardiogenic shock and
post–out-of-hospital cardiac arrest, factors that are usually
associated with poorer outcomes.26,27 Similar to other
studies, in-hospital major bleeding complications were also
lower in overweight and obese patients, which is likely at least
in part due to the increased use of radial access in these
patients.16 Excess dosing of anticoagulant and antiplatelet
drugs is also potentially less likely to occur in more obese
patients, which may also reduce their bleeding risk. Bleeding
has been shown to be independently associated with worse
short- and long-term mortality and therefore may explain our
results to some extent.28
In our study we also found that increased BMI up to the
level of moderate obesity was associated with an increased
use of guideline-based medical therapy, in particular b-
blockers, renin-angiotensin-system blockers, and statins.
Previous studies have shown that increased use of evi-
dence-based cardiovascular medications is associated with
lower long-term mortality after PCI.29 Nonpharmacological
measures such as smoking cessation, dietary counseling, and
cardiac rehabilitation referral have been shown to be
employed more frequently in overweight and obese patients
Table 4. Multi-Variable Cox-Proportional Hazards Modeling
for NDI-Linked Mortality
Hazard Ratio 95% CI P Value
eGFR
eGFR >60 mL/min per
1.73 m2
1 (ref)
eGFR 30 to 60 mL/min per
1.73 m2
1.45 1.33 to 1.58 <0.001
eGFR <30 mL/min per
1.73 m2
3.46 3.03 to 3.95 <0.001
Cardiogenic shock 2.98 2.57 to 3.44 <0.001
Left ventricular ejection fraction
Left ventricular ejection
fraction >45%
1 (ref)
Left ventricular ejection
fraction 30% to 45%
1.57 1.44 to 1.70 <0.001
Left ventricular ejection
fraction <30%
2.50 2.12 to 2.94 <0.001
Chronic obstructive airways
disease
2.11 1.90 to 2.34 <0.001
Out-of-hospital cardiac arrest 1.76 1.47 to 2.10 <0.001
BMI category
BMI 18.5 to 24.9 kg/m2 1 (ref)
BMI 25.0 to 29.9 kg/m2 0.85 0.78 to 0.93 <0.001
BMI 30.0 to 34.9 kg/m2 0.85 0.76 to 0.94 0.002
BMI 35.0 to 39.9 kg/m2 0.95 0.80 to 1.12 0.543
BMI ≥40.0 kg/m2 1.33 1.07 to 1.65 0.010
Diabetes mellitus 1.45 1.34 to 1.57 <0.001
Peripheral vascular disease 1.44 1.29 to 1.60 <0.001
Obstructive sleep apnea 1.39 1.19 to 1.63 <0.001
Previous coronary artery
bypass graft surgery
1.37 1.17 to 1.60 <0.001
Previous stroke 1.35 1.21 to 1.51 <0.001
Left main disease 1.31 1.04 to 1.64 0.023
Multivessel disease 1.25 1.16 to 1.36 <0.001
Previous myocardial
infarction
1.19 1.10 to 1.30 <0.001
Hypertension 1.11 1.01 to 1.22 0.034
Age (per year increase) 1.06 1.05 to 1.06 <0.001
Drug-eluting stent use 0.79 0.73 to 0.85 <0.001
BMI indicates body mass index; eGFR, estimated glomerular filtration rate; NDI, National
Death Index.
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as well, which could also account for the improved out-
comes.30,31
With an increase in the proportion of overweight and obese
individuals in the general population as well as in those
undergoing PCI, it has also been proposed that the worse
prognosis observed in patients with normal BMI may be due
to the effect of residual confounding.17,19 Given that 67% of
the Australian population are overweight or obese, even
having a normal BMI may potentially reflect the presence of
unmeasured serious comorbidities that carry substantial
mortality hazard.32 Previous studies have indeed shown that
patients with low BMI have higher rates of noncardiac
mortality.33,34 In our study we also observed an inverse
relationship between BMI and the presence of comorbidities
such as chronic obstructive pulmonary disease and peripheral
vascular disease. However, we were unable to account for the
prevalence of serious conditions such as cancer, dementia,
malnutrition, and overall measures of frailty, which could
explain the higher mortality in patients even with normal
BMI.35
Finally, there is also evidence that adipose tissue may itself
have potentially cardioprotective effects by producing hor-
mones such as leptin and adiponectin.36 These hormones
have anti-inflammatory and antiapoptotic properties and
might reduce infarct size.37,38 Obesity-inducing high-fat diets
in rats have also been shown to be cardioprotective.39
Obesity may also be protective against malnutrition following
a major cardiac event or procedure.40 However, the increase
in mortality seen in patients with extreme, class III obesity
suggests that there is likely a threshold effect. Therefore, as
BMI increases to over 40 kg/m2, the protective effects of
milder degrees of obesity may be abrogated by the delete-
rious effects of extreme obesity including alterations in
cardiac structure and function, potentiation of an inflamma-
tory and prothrombotic state, and increased noncardiovascu-
lar mortality.41-43 This may explain why the obesity paradox
did not extend to the extremely obese in several studies
including ours.17,44
Limitations
Our study has several limitations. First, due to the retrospec-
tive design of this study, we were unable to account for all
potential confounding factors such as socioeconomic status,
noncardiac comorbidities such as cancer, as well as measures
of frailty, which can all potentially affect post-PCI short- and
long-term mortality. Second, BMI measured at the time of PCI
might not necessarily reflect BMI at the time of linkage with
the NDI, which was on average 4 years after the index PCI
procedure. It is also not known how dynamic weight changes
might impact clinical outcomes among patients whose weight
had changed between the index PCI and the time of NDI
linkage. Third, we did not capture measures of central
adiposity such as waist circumference and waist-to-hip ratio,
which have been shown to be better predictors of cardiovas-
cular outcomes than BMI alone.45,46 However, BMI is the
measurement used and endorsed by the World Health
Organization to classify obesity worldwide given its simple
and easily quantifiable nature, and it was therefore chosen for
this study. Finally, we did not have data on the use of
guideline-recommended secondary prevention therapy
beyond 30 days after PCI, which might also have explained
some of the differences in mortality among BMI groups.40
Conclusions
In conclusion, there remains an obesity paradox with regard
to long-term mortality in patients undergoing PCI in contem-
porary practice, with mildly obese patients having the lowest
adjusted mortality hazard. However, this protective effect
does not extend to patients with extreme obesity. Factors
behind this phenomenon are likely multifactorial and require
further mechanistic and epidemiological studies.
Acknowledgments
We thank the Steering Committee and all the investigators and data
managers at the institutions that participate in the MIG registry. The
Table 5. Medication Use at 30-Day Follow-Up
BMI 18.5 to
24.9 kg/m2
BMI 25.0 to
29.9 kg/m2
BMI 30.0 to
34.9 kg/m2
BMI 35.0 to
39.9 kg/m2 BMI ≥40 kg/m2 P for Trend
Aspirin 5688 (97.7) 9690 (97.4) 5299 (97.6) 1733 (98.1) 758 (96.3) 0.628
Clopidogrel/prasugrel/ticagrelor 5592 (96.1) 9590 (96.4) 5188 (95.5) 1688 (95.6) 751 (95.6) 0.045
b-Blocker 4494 (77.7) 7827 (79.2) 4295 (80.0) 1410 (80.5) 617 (79.4) 0.003
ACEi/ARB 4340 (75.0) 7792 (78.8) 4424 (82.2) 1491 (85.1) 647 (83.3) <0.001
Statin 5450 (94.2) 9403 (95.1) 5096 (94.5) 1673 (95.3) 747 (95.5) 0.119
Data expressed as numbers (%). ACEi indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BMI, body mass index.
DOI: 10.1161/JAHA.119.012860 Journal of the American Heart Association 8
Extreme Obesity and Long-Term Outcomes After PCI Biswas et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
MIG Steering Committee consisted of Professor Chris Reid, Associ-
ate Professor Andrew Ajani, Professor Stephen Duffy, Associate
Professor David Clark, Dr Melanie Freeman, Dr Chin Hiew, Associate
Professor Ernesto Oqueli, and Ms Angela Brennan. The following
investigators, data managers, and institutions participated in the MIG
Database: at Alfred Hospital, S. J. Duffy, J. A. Shaw, A. Walton, A.
Dart, A. Broughton, C. Keighley, C. Hengel, K. H. Peter, D. Stub, W.
Chan, M. Freilich, N. Htun, R. Prakash, S. Biswas, and L. Selkrig; at
Austin Hospital, D. J. Clark, O. Farouque, M. Horrigan, J. Johns, L.
Oliver, J. Brennan, R. Chan, G. Proimos, T. Dortimer, B. Chan, R. Huq,
D. Fernando, M. Yudi, L. Brown, A. Al-Fiadh, J. Ramchand, and S.
Picardo; at Ballarat Base Hospital, E. Oqueli, A. Sharma, N. Ryan, and
C. Barry; at Box Hill Hospital, M. Freeman, J. Cooke, L. Roberts, J.
Chandrasekhar, A. Teh, M. Rowe, G. Proimos, Y. Cheong, C. Goods,
D. Fernando, L. Marceddo, K. Soon, and D. Natarajan; at Monash
University, C. Reid, N. Andrianopoulos, A. L. Brennan, D. Dinh, and B.
P. Yan; at Royal Melbourne Hospital, A. E. Ajani, R. Warren, D.
Eccleston, J. Lefkovits, R. Iyer, R. Gurvitch, W. Wilson, M. Brooks, and
L. P. Dawson; at University Hospital Geelong, C. Hiew, M. Sebastian,
T. Yip, M. Mok, C. Jaworski, A. Hutchison, B. McDonald, R. Pavletich,
and N. Herbert.
Sources of Funding
Dr Biswas is supported by scholarships from the National
Heart Foundation (NHF) of Australia (reference no. 101518),
National Health and Medical Research Council of Australia
(NHMRC) Cardiovascular Centre of Research Excellence in
Cardiovascular Outcomes Improvement (CRE-COI), and the
Australian Government Research Training Program. Dr Noa-
man is supported by a scholarship from the NHMRC CRE-COI.
Professor Duffy’s work is supported by a NHMRC grant
(reference no. 1111170). Professor Reid is supported by a
NHMRC Principal Research Fellowship (reference no.
11136372). Associate Professor Stub is supported by a
NHF Future Leader Fellowship (reference no. 101908) and a
Viertel Foundation Clinical Investigator award. Associate
Professor Chan is supported by the Alfred Hospital Research
Trust and the Harold Cora Brennan Benevolent Trust. The
Melbourne Interventional Group acknowledges funding from
Abbott, Astra-Zeneca, Medtronic, MSD, Pfizer, Servier, and
The Medicines Company. These companies do not have
access to data and do not have the right to review
manuscripts or abstracts before publication. Medtronic also
assisted in defraying the publication cost of this article with
an unrestricted educational grant.
Disclosures
None.
References
1. World Health Organization. Obesity and Overweight. Fact sheet. 2018.
Available at: http://www.who.int/news-room/fact-sheets/detail/obesity-
and-overweight. Accessed May 3, 2018.
2. National Heart Foundation of Australia. Overweight and obesity statistics.
2015. Available at: https://www.heartfoundation.org.au/about-us/what-we-
do/heart-disease-in-australia/overweight-and-obesity-statistics. Accessed
October 3, 2017.
3. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R,
Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large
prospective cohort of persons 50 to 71 years old. N Engl J Med.
2006;355:763–778.
4. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent
risk factor for cardiovascular disease: a 26-year follow-up of participants in the
Framingham Heart Study. Circulation. 1983;67:968–977.
5. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, Kosiborod M,
Portnay EL, Sokol SI, Bader F, Krumholz HM. The obesity paradox: body mass
index and outcomes in patients with heart failure. Arch Intern Med.
2005;165:55–61.
6. Prabhakar G, Haan CK, Peterson ED, Coombs LP, Cruzzavala JL, Murray GF.
The risks of moderate and extreme obesity for coronary artery bypass grafting
outcomes: a study from the Society of Thoracic Surgeons’ database. Ann
Thorac Surg. 2002; 74:1125–1130; discussion 1130–1121.
7. Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of
BMI with overall and cause-specific mortality: a population-based cohort study
of 3.6 million adults in the UK. Lancet Diabetes Endocrinol. 2018; 6:944–953.
8. Lancefield T, Clark DJ, Andrianopoulos N, Brennan AL, Reid CM, Johns J,
Freeman M, Charter K, Duffy SJ, Ajani AE, Proietto J, Farouque O, Registry MIG.
Is there an obesity paradox after percutaneous coronary intervention in the
contemporary era? An analysis from a multicenter Australian registry. JACC
Cardiovasc Interv. 2010;3:660–668.
9. McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE,
Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann
KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A,
Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P,
Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan
Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson
DB, Menzies AM, Davies MA. Association of body-mass index and outcomes in
patients with metastatic melanoma treated with targeted therapy,
immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Lancet Oncol. 2018;19:310–322.
10. Ellis SG, Elliott J, Horrigan M, Raymond RE, Howell G. Low-normal or excessive
body mass index: newly identified and powerful risk factors for death and
other complications with percutaneous coronary intervention. Am J Cardiol.
1996;78:642–646.
11. Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, Ahmed
LM, Kent KM, Pichard AD, Suddath WO, Satler LF, Lindsay J Jr. The impact of
obesity on the short-term and long-term outcomes after percutaneous
coronary intervention: the obesity paradox? J Am Coll Cardiol. 2002;39:578–
584.
12. Minutello RM, Chou ET, Hong MK, Bergman G, Parikh M, Iacovone F, Wong SC.
Impact of body mass index on in-hospital outcomes following percutaneous
coronary intervention (report from the New York State Angioplasty Registry).
Am J Cardiol. 2004;93:1229–1232.
13. Niedziela J, Hudzik B, Niedziela N, Gasior M, Gierlotka M, Wasilewski J, Myrda
K, Lekston A, Polonski L, Rozentryt P. The obesity paradox in acute coronary
syndrome: a meta-analysis. Eur J Epidemiol. 2014;29:801–812.
14. Payvar S, Kim S, Rao SV, Krone R, Neely M, Paladugu N, Daggubati R. In-
hospital outcomes of percutaneous coronary interventions in extremely obese
and normal-weight patients: findings from the NCDR (National Cardiovascular
Data Registry). J Am Coll Cardiol. 2013;62:692–696.
15. Neeland IJ, Das SR, Simon DN, Diercks DB, Alexander KP, Wang TY, de Lemos
JA. The obesity paradox, extreme obesity, and long-term outcomes in older
adults with ST-segment elevation myocardial infarction: results from the
NCDR. Eur Heart J Qual Care Clin Outcomes. 2017;3:183–191.
16. Holroyd EW, Sirker A, Kwok CS, Kontopantelis E, Ludman PF, De Belder MA,
Butler R, Cotton J, Zaman A, Mamas MA. The relationship of body mass index
to percutaneous coronary intervention outcomes: does the obesity paradox
exist in contemporary percutaneous coronary intervention cohorts? Insights
from the British Cardiovascular Intervention Society Registry. JACC Cardiovasc
Interv. 2017;10:1283–1292.
17. Das SR, Alexander KP, Chen AY, Powell-Wiley TM, Diercks DB, Peterson ED,
Roe MT, de Lemos JA. Impact of body weight and extreme obesity on the
presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-
segment elevation myocardial infarction: results From the NCDR (National
Cardiovascular Data Registry). J Am Coll Cardiol. 2011;58:2642–2650.
18. Akin I, T€olg R, Hochadel M, Bergmann MW, Khattab AA, Schneider S, Senges J,
Kuck K-H, Richardt G, Nienaber CA. No evidence of “Obesity Paradox” after
treatment with drug-eluting stents in a routine clinical practice: results from
the prospective multicenter German DES.DE (German Drug-Eluting Stent)
Registry. JACC Cardiovasc Interv. 2012; 5:162–169.
DOI: 10.1161/JAHA.119.012860 Journal of the American Heart Association 9
Extreme Obesity and Long-Term Outcomes After PCI Biswas et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
19. Buschur ME, Smith D, Share D, Campbell W, Mattichak S, Sharma M, Gurm
HS. The burgeoning epidemic of morbid obesity in patients undergoing
percutaneous coronary intervention: insight from the Blue Cross Blue Shield of
Michigan cardiovascular consortium. J Am Coll Cardiol. 2013;62:685–691.
20. Oreopoulos A, Padwal R, Norris CM, Mullen JC, Pretorius V, Kalantar-Zadeh K.
Effect of obesity on short- and long-term mortality postcoronary revascular-
ization: a meta-analysis. Obesity (Silver Spring). 2008;16:442–450.
21. World Health Organization. Obesity: Preventing and Managing the Global
Epidemic. Report of a WHO Consultation on Obesity. WHO Technical Series.
2000.
22. Ajani AE, Szto G, Duffy SJ, Eccleston D, Clark DJ, Lefkovits J, Chew DP, Warren
R, Black A, New G, Walton A, Lew R, Shaw J, Horrigan M, Sebastian M, Yan BP,
Brennan A, Meehan A, Reid C, Krum H. The foundation and launch of the
Melbourne Interventional Group: a collaborative interventional cardiology
project. Heart Lung Circ. 2006;15:44–47.
23. Chan W, Clark DJ, Ajani AE, Yap CH, Andrianopoulos N, Brennan AL, Dinh DT,
Shardey GC, Smith JA, Reid CM, Duffy SJ. Progress towards a National Cardiac
Procedure Database–development of the Australasian Society of Cardiac and
Thoracic Surgeons (ASCTS) and Melbourne Interventional Group (MIG)
registries. Heart Lung Circ. 2011;20:10–18.
24. Sharma A, Vallakati A, Einstein AJ, Lavie CJ, Arbab-Zadeh A, Lopez-Jimenez F,
Mukherjee D, Lichstein E. Relationship of body mass index with total mortality,
cardiovascular mortality, and myocardial infarction after coronary revascular-
ization: evidence from a meta-analysis. Mayo Clin Proc. 2014;89:1080–1100.
25. Molenaar EA, Hwang SJ, Vasan RS, Grobbee DE, Meigs JB, D’Agostino RB Sr,
Levy D, Fox CS. Burden and rates of treatment and control of cardiovascular
disease risk factors in obesity: the Framingham Heart Study. Diabetes Care.
2008;31:1367–1372.
26. Kunadian V, Qiu W, Ludman P, Redwood S, Curzen N, Stables R, Gunn J,
Gershlick A; National Institute for Cardiovascular Outcomes Research.
Outcomes in patients with cardiogenic shock following percutaneous coronary
intervention in the contemporary era: an analysis from the BCIS database
(British Cardiovascular Intervention Society). JACC Cardiovasc Interv. 2014;
7:1374–1385.
27. Lim HS, Stub D, Ajani AE, Andrianopoulos N, Reid CM, Charter K, Black A,
Smith K, New G, Chan W, Lim CC, Farouque O, Shaw J, Brennan A, Duffy SJ,
Clark DJ. Survival in patients with myocardial infarction complicated by out-of-
hospital cardiac arrest undergoing emergency percutaneous coronary inter-
vention. Int J Cardiol. 2013;166:425–430.
28. Kwok CS, Khan MA, Rao SV, Kinnaird T, Sperrin M, Buchan I, de Belder MA,
Ludman PF, Nolan J, Loke YK, Mamas MA. Access and non-access site
bleeding after percutaneous coronary intervention and risk of subsequent
mortality and major adverse cardiovascular events: systematic review and
meta-analysis. Circ Cardiovasc Interv. 2015; 8:pii: e001645.
29. Jaber WA, Lennon RJ, Mathew V, Holmes DR Jr, Lerman A, Rihal CS. Application
of evidence-based medical therapy is associated with improved outcomes
after percutaneous coronary intervention and is a valid quality indicator. J Am
Coll Cardiol. 2005;46:1473–1478.
30. Mongraw-Chaffin ML, Peters SAE, Huxley RR, Woodward M. The sex-specific
association between BMI and coronary heart disease: a systematic review and
meta-analysis of 95 cohorts with 1.2 million participants. Lancet Diabetes
Endocrinol. 2015; 3:437–449.
31. Diercks DB, Roe MT, Mulgund J, Pollack CV Jr, Kirk JD, Gibler WB, Ohman EM,
Smith SC Jr, Boden WE, Peterson ED. The obesity paradox in non-ST-segment
elevation acute coronary syndromes: results from the Can Rapid risk
stratification of Unstable angina patients Suppress ADverse outcomes with
Early implementation of the American College of Cardiology/American Heart
Association Guidelines Quality Improvement Initiative. Am Heart J.
2006;152:140–148.
32. Australian Bureau of Statistics. National Health Survey First results, Australia
2017-2018. ABS Catalogue No. 4364.0.55.001. 2018. Available at: https://
www.ausstats.abs.gov.au/ausstats/subscriber.nsf/0/
4B3976684C09F43FCA258399001CE630/$File/4364.0.55.001%20-%20na
tional%20health%20survey,%20first%20results,%202017-18.pdf. Accessed
June 15, 2019.
33. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and
mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;
341:1097–1105.
34. Tremblay A, Bandi V. Impact of body mass index on outcomes following critical
care. Chest. 2003;123:1202–1207.
35. Wada H, Dohi T, Miyauchi K, Doi S, Naito R, Konishi H, Tsuboi S, Ogita M, Kasai
T, Hassan A, Okazaki S, Isoda K, Suwa S, Daida H. Prognostic impact of the
geriatric nutritional risk index on long-term outcomes in patients who
underwent percutaneous coronary intervention. Am J Cardiol. 2017;
119:1740–1745.
36. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity,
diabetes, and vascular diseases. Eur Heart J. 2008;29:2959–2971.
37. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L,
Goldstein BJ, Ma XL. Adiponectin cardioprotection after myocardial ischemia/
reperfusion involves the reduction of oxidative/nitrative stress. Circulation.
2007;115:1408–1416.
38. Smith CC, Mocanu MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM.
Leptin, the obesity-associated hormone, exhibits direct cardioprotective
effects. Br J Pharmacol. 2006;149:5–13.
39. Salie R, Huisamen B, Lochner A. High carbohydrate and high fat diets protect
the heart against ischaemia/reperfusion injury. Cardiovasc Diabetol.
2014;13:109.
40. Bundhun PK, Li N, Chen MH. Does an obesity paradox really exist after
cardiovascular intervention? A systematic review and meta-analysis of
randomized controlled trials and observational studies. Medicine (Baltimore).
2015;94:e1910.
41. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk
factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925–
1932.
42. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in
obesity. J Endocrinol Invest. 2002;25:899–904.
43. Cottam DR, Mattar SG, Barinas-Mitchell E, Eid G, Kuller L, Kelley DE, Schauer
PR. The chronic inflammatory hypothesis for the morbidity associated with
morbid obesity: implications and effects of weight loss. Obes Surg.
2004;14:589–600.
44. Angeras O, Albertsson P, Karason K, Ramunddal T, Matejka G, James S,
Lagerqvist B, Rosengren A, Omerovic E. Evidence for obesity paradox in
patients with acute coronary syndromes: a report from the Swedish
Coronary Angiography and Angioplasty Registry. Eur Heart J. 2013;34:345–
353.
45. Myint PK, Kwok CS, Luben RN, Wareham NJ, Khaw KT. Body fat percentage,
body mass index and waist-to-hip ratio as predictors of mortality and
cardiovascular disease. Heart. 2014;100:1613–1619.
46. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, van
der Schouw YT, Spencer E, Moons KG, Tjonneland A, Halkjaer J, Jensen MK,
Stegger J, Clavel-Chapelon F, Boutron-Ruault MC, Chajes V, Linseisen J, Kaaks
R, Trichopoulou A, Trichopoulos D, Bamia C, Sieri S, Palli D, Tumino R, Vineis P,
Panico S, Peeters PH, May AM, Bueno-de-Mesquita HB, van Duijnhoven FJ,
Hallmans G, Weinehall L, Manjer J, Hedblad B, Lund E, Agudo A, Arriola L,
Barricarte A, Navarro C, Martinez C, Quiros JR, Key T, Bingham S, Khaw KT,
Boffetta P, Jenab M, Ferrari P, Riboli E. General and abdominal adiposity and
risk of death in Europe. N Engl J Med. 2008;359:2105–2120.
DOI: 10.1161/JAHA.119.012860 Journal of the American Heart Association 10
Extreme Obesity and Long-Term Outcomes After PCI Biswas et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
  
 
 
Supplemental Material 
 
Table S1. Data dictionary for variables in Melbourne Interventional Group Registry. 
 
Variable Definition 
Baseline characteristics 
Body mass index Calculated from weight (in kilograms in light clothing) and height (in 
metres in bare feet), using formula: weight / height2 
Diabetes mellitus Documented history of diabetes regardless of duration of disease or 
need for anti-diabetic agents 
Hypertension Must have one of the following documented findings 
- History of hypertension diagnosed and treated with 
medication, diet and/or exercise.   
- Blood pressure >140 systolic or >90 diastolic on at least 2 
occasions.   
- Currently on antihypertensive medication.   
Dyslipidemia Must have one of the following documented findings 
- History of dyslipidemia diagnosed and/or treated by a 
physician.   
- Cholesterol > 5.0 mmol/L, HDL < 1.0mmol/L or Triglycerides 
> 2.0mmol/L.   
Smoking status History confirming any form of tobacco use in the past. This includes 
cigarettes, cigar and/or pipe. Choose from:  
- Currently smoking - within 1 month of this admission   
- Previously smoked - more than 1 month prior to this 
admission   
- Never smoked   
Family history of coronary artery disease Any first-degree relatives of the patient (parents, siblings, children) 
who have any of the following at age <60 years:  
- Coronary artery disease (angina, previous CABG or PCI)  
- MI 
- Sudden cardiac death without an obvious cause  
Estimated glomerular filtration rate Calculated using Cockroft-Gault formula using last serum creatinine 
level recorded prior to the current PCI 
  
Chronic obstructive pulmonary disease Documented history of chronic obstructive pulmonary disease - a 
slowly progressive disease that is characterized by a gradual loss of 
lung function. Includes chronic bronchitis, chronic obstructive 
bronchitis, or emphysema, or combinations of these conditions. 
Diagnosis of COPD is confirmed by the presence of airway 
obstruction on testing with spirometry.   
Obstructive sleep apnea Patient reports knowledge of, or has previously been diagnosed with 
obstructive sleep apnoea  
Peripheral vascular disease Evidence of either chronic or acute PVD. The presence of PVD must 
be demonstrated by vascular reconstruction or amputation for arterial 
insufficiency, bypass surgery or percutaneous intervention.  
Previous stroke History of stroke or cerebrovascular accident (CVA), resulting from 
an ischaemic or intracerebral haemorrhagic event ONLY where the 
patient suffered a loss of neurological function with residual 
symptoms remaining for at least 72 hours  
Previous myocardial infarct (MI) At least one documented MI greater than 7 days prior to admission.  
An MI is evidenced by any of the following.  
1. A rise and fall of cardiac biomarkers (Troponin, CK or CK-MB) 
with at least one value in an abnormal range for that laboratory 
above the upper reference limit (URL) of normal (i.e. above the 
99th percentile of the URL measured with a coefficient of 
variation ≤10%).  
In partnership with at least one of the following manifestations of 
myocardial ischemia.  
a. Ischemic symptoms.   
b. ECG changes indicative of new ischemia (new ST-T 
changes, new left bundle branch block (LBBB) or loss of R 
wave voltage.   
c. Development of pathological Q waves in two or more 
contiguous leads on the ECG (or equivalent findings for true 
posterior MI)   
d. Imaging evidence of new loss of viable myocardium or new 
regional wall motion abnormality.   
e. Documentation in the medical record of the diagnosis of 
acute myocardial infarction based on the cardiac biomarker 
pattern in the absence of any items enumerated in a-d due to 
conditions that may mask their appearance (e.g. peri-
operative infarct when the patient cannot report ischemic 
symptoms, baseline LBBB or ventricular pacing).   
2. ECG changes associated with prior MI can include the following 
(with or without prior symptoms):  
a. Any Q wave in leads V2-V3 ≥ 0.02sec or QS complex in leads 
V2 & V3.   
b. Q wave ≥ 0.03 sec & ≥ 0.1mV deep or QS complex in leads I, 
II, aVL, aVF, or V4-V6 in any two leads of a contiguous lead 
grouping (I, aVL, V6; V4-V6; II, III, and aVF).   
c. R-wave ≥ 0.04 sec in V1-V2 and R/S ≥ 1 with a concordant 
positive T wave in the absence of a conduction defect.   
3. Imaging evidence of a region with new loss of viable 
myocardium at rest in the absence of non-ischemic cause. This 
can be manifested as:  
a. Echocardiographic, computed tomography (CT), magnetic 
resonance (MR), ventriculographic or nuclear imaging 
evidence of left ventricular (LV) thinning or scarring and 
failure to contract (i.e., hypokinesis, akinesis, or dyskinesis)   
b. Fixed (non-reversible) perfusion defects on nuclear 
radioisotope imaging (e.g. MIBI, Thallium)   
4. Medical records documentation of prior MI.   
Previous percutaneous coronary intervention Patient has had a prior Percutaneous Transluminal Coronary 
Angioplasty, Coronary Atherectomy, and/or coronary stent done at 
any time prior to the current PCI procedure (this may have included a 
PCI performed during the current admission) 
Previous coronary artery bypass graft surgery Patient has undergone a previous Coronary Artery Bypass (CABG) 
surgery prior to the current PCI procedure  
Presentation and PCI characteristics 
Stable angina Angina without a change in frequency or pattern for the 6 weeks prior 
to presentation/procedure. Angina is controlled by rest and/or 
sublingual/oral/transcutaneous medications.  
Unstable angina Symptoms must include at least one of the following: 
1. Angina that occurred at rest and was prolonged, usually 
lasting >20 mins 
2. New-onset angina of at least CCS class III severity 
3. Recent acceleration of angina reflected by an increase in 
severity of at least 1 CCS class (to at least CCS class III)  
Non ST-elevation myocardial infarction (NSTEMI) At least one of the following biomarkers for detecting myocardial 
necrosis must be present:  
1. Troponin T or I: Maximal concentration of Troponin T or I 
greater than the MI diagnostic limit on at least one occasion 
within 24 hours from the index clinical event;  
2. CK-MB: Maximal value of CK-MB >2x the upper limit of 
normal (ULN) on one occasion during the first hours after the 
index clinical event; OR Maximal value of CK-MB (preferable 
CK-MB mass) > ULN on two successive samples.  
3. Total CK: Only where Troponin or CK-MB assays are 
unavailable, total CK >2x the ULN (or the B fraction of CK) 
may be employed.  
AND one of the following: 
1. Either ST segment depression or T wave abnormalities in the 
ECG; or  
2. Ischaemic symptoms in the presence or absence of chest 
discomfort. Ischaemic symptoms may include: unexplained 
nausea and vomiting or persistent shortness of breath 
secondary to left ventricular failure or unexplained weakness, 
dizziness, light-headedness, or syncope.  
ST-elevation myocardial infarction (STEMI) At least one of the following biomarkers for detecting myocardial 
necrosis must be present:  
1. Troponin T or I: Maximal concentration of Troponin T or I 
greater than the MI diagnostic limit on at least one occasion 
within 24 hours from the index clinical event;  
2. CK-MB: Maximal value of CK-MB >2x the upper limit of 
normal (ULN) on one occasion during the first hours after the 
index clinical event; OR Maximal value of CK-MB (preferable 
CK-MB mass) > ULN on two successive samples.  
3. Total CK: Only where Troponin or CK-MB assays are 
unavailable, total CK >2x the ULN (or the B fraction of CK) 
may be employed.  
AND one of the following: 
1. ST-segment elevation: New or presumed new ST segment 
elevation at the J point in two or more contiguous leads with 
the cut-off points ≥ 0.2mV in leads V1, V2, or V3, or ≥0.1 mV 
in other leads.   
2. Development of any Q wave in leads V1 through V3, or the 
development of a Q-wave ≥ 30ms (0.03s) in leads I, II, aVL, 
aVF, V4, V5, or V6. (Q wave changes must be present in any 
two contiguous leads, and be ≥1mm in depth).   
Out-of-hospital cardiac arrest at presentation Patient has experienced an out of hospital cardiac arrest (i.e. the lack 
of effective cardiac output) including if the person was under cardiac 
arrest at the time of presentation to the hospital.  
Cardiogenic shock All of the following must apply at the time of index PCI: 
1. Sustained (>30 minutes) episode of systolic blood pressure 
<90 mm Hg (or vasopressors required to maintain BP >90 
mm Hg); AND   
2. Evidence of elevated filling pressures (e.g. pulmonary 
congestion on examination or chest radiograph); AND   
3. Evidence of end organ hypoperfusion (e.g. urine output 
30mL/hour; or cold/diaphoretic extremities; or altered mental 
status, etc.).   
Left ventricular ejection fraction Left ventricular ejection fraction measured immediately post PCI with 
angiography or prior to discharge with echocardiography  
Multi-vessel disease Lesion of ≥50% stenosis in 2 or more coronary systems.   
Coronary systems are defined as: left anterior descending (LAD)-
Diagonal / left circumflex-marginal (Cx-OM) / right coronary artery 
(RCA). LAD-Diagonal is one coronary system as is Cx-OM and the 
RCA. Left main coronary artery (LMCA) is 2 coronary systems as it 
gives rise to the LAD & Cx systems, therefore is multi-vessel 
disease.   
Left main disease Lesion of ≥50% stenosis in the left main coronary artery.   
Chronic total occlusion Lesion treated was presumed to be a CTO defined as being >3 
months old and/or bridging collaterals  
AHA/ACC class B2/C lesion Lesion type according to ACC/AHA guidelines: 
- B2: more than one type B characteristic (lesion moderately 
complex, tubular (10- 20mm), eccentric, moderately tortuosity 
of proximal segments, lesion in moderately angulated 
segment (>45 degrees but < 90 degrees), irregular contour, 
moderate to heavy calcification, total occlusions less than 3 
months old, ostial in location, bifurcation lesions requiring 
double guide wires, some thrombus present). 
- C: severely complex diffuse (>20mm), excessive tortuosity of 
proximal segment, lesion in extremely angulated segment > 
90 degrees, total occlusion greater than 3 months old or 
bridging collaterals, inability to protect major side branches, 
degenerated vein graft with friable lesions.   
PCI complications:  
- Dissection If a dissection > 5 mm was observed during the PCI procedure for 
the treated segment (or for a significant side branch).  
Dissection is defined as the appearance of contrast materials outside 
of the expected luminal dimensions of the target vessel and 
extending longitudinally beyond the length of the lesion.  
- Perforation If a coronary perforation occurred during the procedure for the 
treated segment.  
A coronary artery perforation occurs when there is angiographic or 
clinical evidence of a dissection or intimal tear that extends through 
the full thickness of the arterial wall. This does not include pre-
existing AV fistula and other coronary anomalies.  
- Transient no-reflow If there was a period of temporary lack of flow distal to the treated 
segment during the PCI procedure 
- Persistent no-reflow If there was persistent lack of flow distal to the treated segment 
during the PCI procedure 
Unsuccessful PCI >50% residual stenosis for a lesion treated by balloon angioplasty 
only OR >20% residual stenosis for stented lesion 
In-hospital outcomes 
Death Patient died in hospital during or after the index PCI procedure, but 
prior to discharge 
Cardiac death Primary cause of death was cardiac i.e. sudden death, myocardial 
infarction, heart failure or arrhythmia 
Myocardial infarction New presence of a peri-procedural MI during the cath lab visit or 
after lab visit until discharge (or before any subsequent lab visits) as 
documented by at least 1 of the following criteria: 
- Evolutionary ST-segment elevations, development of new Q- 
waves in 2 or more contiguous ECG leads, or new or 
presumably new LBBB pattern on the ECG.   
- Biochemical evidence of myocardial necrosis. This can be 
manifested as:  
a) CK-MB > 3x the upper limit of normal or, if CK-MB not 
available   
b) Total CK > 3x upper limit of normal. (Because normal 
limits of certain blood tests may vary, please check with 
your lab for normal limits for CK-MB and total CK).   
 
Note: Must be distinct from the index event   
Heart failure Patient experienced documented new onset HF or an acute 
reoccurrence of HF which necessitated new or increased 
pharmacologic therapy during the cath lab visit or after lab visit until 
discharge (or before any subsequent lab visits).  
HF can be diagnosed based on careful history and physical exam, or 
by one of the following criteria:  
- Paroxysmal nocturnal dyspnoea (PND) and/or fatigue 
- Dyspnoea on exertion (DOE) due to heart failure 
- Chest X-Ray (CXR) showing pulmonary congestion 
- Pedal oedema or dyspnoea treated with medical therapy for 
heart failure   
Acute kidney injury Patient experienced new acute or worsening renal failure after the 
cardiac catheter lab visit but prior to discharge, defined as an 
absolute rise of serum creatinine > 44.2 mmol/L OR > 25% up to 5 
days after the index PCI, when compared to baseline creatinine 
immediately prior to PCI 
Major bleeding Bleeding that occurred during or after the cath lab visit until 
discharge. The bleeding should require a transfusion and/or prolong 
the hospital stay and/or cause a drop in haemoglobin > 3.0 g/dL.  
Stroke The patient experienced a stroke or new central neurologic deficit 
(persisting for > 72 hours) during the cardiac catheter lab visit, after 
the lab visit, but prior to discharge and/or any subsequent lab visits.  
Stroke is evidenced by persistent loss of neurological function 
caused by an ischaemic or haemorrhagic event.  
Target vessel revascularisation  
Major adverse cardiovascular events (MACE) Composite endpoint of death, myocardial infarction and target vessel 
revascularization (any revascularisation due to restenosis/occlusion 
within the target coronary artery and/or the same arterial branch that 
was treated during the index PCI. This includes any percutaneous 
revascularisation within the same arterial branch treated during the 
index PCI, regardless of whether the index PCI was successful). 
30-day outcomes 
Death Patient died in hospital during or after the index PCI procedure, but 
prior to discharge 
Cardiac death Primary cause of death was cardiac i.e. sudden death, myocardial 
infarction, heart failure or arrhythmia 
Myocardial infarction Readmission with primary reason documented as acute myocardial 
infarction (STEMI or NSTEMI) 
Stroke Readmission with primary reason documented as stroke (loss of 
neurological function persisting for >72 hours caused by an 
ischaemic or haemorrhagic event) 
Target vessel revascularisation Readmission with primary reason documented as revascularization 
by PCI or CABG 
Readmission Any overnight stay in hospital since discharge from the index PCI 
MACE Composite endpoint of death, myocardial infarction and target vessel 
revascularization (any revascularisation due to restenosis/occlusion 
within the target coronary artery and/or the same arterial branch that 
was treated during the index PCI. This includes any percutaneous 
revascularisation within the same arterial branch treated during the 
index PCI, regardless of whether the index PCI was successful). 
Beta-blocker Patients on any of the following medications: metoprolol, atenolol, 
carvedilol, propranolol, bisoprolol, sotalol, labetolol, oxprenolol, 
nebivolol  
Angiotensin converting enzyme inhibitor / angiotensin II 
receptor blocker 
Patients on any of the following medications: perindopril, lisinopril, 
ramipril, enalapril, fosinopril, captopril, quinapril, trandalopril, 
candesartan, telmisartan, irbesartan, losartan, olmesartan, valsartan, 
eprosartan 
Statin Patient on any of the following medications: atorvastatin, fluvastatin, 
pravastatin, rosuvastatin, simvastatin 
 
